Relation between pathomorphological response in tumors after neoadjuvant chemotherapy and clinico-morphological and molecular prognostic factors in patients with breast cancer by Timovska, Yu.O. et al.
Experimental Oncology 31, 231–236, 2009 (December) 231
Individualization of combined treatment of BC pa-
tients is an important component of treatment strategy 
aimed on improvement of remote results [1]. Evaluation 
of tumor PMR after NACT can be used for individuali-
zation of treatment, serving as an indicator of tumor 
sensitivity to applied chemotherapy.
The role of PMR grade combined with ER/PR and 
Her-2/neu status of tumor is not certain [2–5]. Groups 
of patients with the different PMR grades but with BC 
stage and undergoing equal neoadjuvant therapy, 
are heterogeneous by other criteria (grade of differ-
entiation, ER/PR and Her-2/neu status of tumor, age 
of patient).
We have studied BC cases classified into three sub-
types: basal (ER–, PR–, Her-2/neu–), luminal (ER+ and/
or PR+, Her-2neu+/–) and Her-2/neu positive (ER–, PR–, 
Her-2/neu+), which have a different prognosis, various 
responsiveness to therapy and require different treat-
ment approaches [4–14].
The aim of the present research was to determine 
the correlation between tumor PMR after NACT and 
clinico-morphological and molecular prognostic fac-
tors in BC patients, and to determine the possible 
impact of PMR and ER, PR and Her-2/neu BC status 
on the disease course.
MATERIALS AND METHODS
Retrospective study of 247 patients with BC 
of stage IIB cured in City Oncological Hospital (Kiev, 
Ukraine) in 2003–2005 has been performed. The age 
of the patients was from 30 to 70 years (median age of 
54.2 ± 10.5 years). Untreated patients with BC stage 
IIB (T2N1M0, T3N0M0) received two 3-week cycles 
of 5-fluorouracil (5-FU), doxorubicin and cyclophos-
phamide (the CAF regimen). All of them underwent 
surgery after systemic treatment. The morphologi-
cal variant of BC, tumor differentiation grade, lymph 
node metastastasis, PMR grade were evaluated by 
pathomorphological research*.
ER/PR and Her-2/neu expression were evaluated 
by immunohistochemical analysis. ER and PR expres-
sion by less than 5% of tumors cells was considered as 
expression negative. The Her-2/neu status of tumor 
was considered positive in cases with strong complete 
*The research was performed according to the regulations of insti-
tution’s Ethical Committee.
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membrane Her-2/neu expression (score 3+). All cases 
with ambiguous expression of Her-2/neu (score 2+) 
were previously analyzed by FISH analysis as it is 
described [15, 16]. According to the data of immuno-
histochemical analysis, we have sudivided BC cases 
into four groups: basal subtype (ER–, PR–, Her2/neu–), 
luminal A (ER+ and/or PR+, Her2/neu–), luminal B (ER+ 
and/or PR+, Her2/neu+), and Her-2/neu positive (ER–, 
PR–, Her2/neu+).
The NACT was identical for all groups of BC pa-
tients — two 3-week CAF cycles.
The correlation between the parameters was ana-
lyzed using Spearman’s coefficient. Patient’s survival 
was analyzed by Kaplan – Meier method. The association 
between PMR grade with the risk of disease relapse was 
estimated by Cox regression analysis. Significance of 
mentioned coefficients was evaluated by χ2 test. P values 
< 0.05 were considered statistically significant.
RESULTS AND DISCUSSION
Clinico-morphological characteristics of the pa-
tients with BC were different. There were 232 (96%) BC 
patients with defined histological type of tumor: inva-
sive ductal cancer (177 (76.3%) cases), lobular cancer 
(24 (10.4%) cases), ductal-lobular cancer (10(4.3%) 
cases), mucous cancer (16 (6.9%) cases), and papil-
lary cancer (5 (2.1%) cases); in 15 (4%) patients with 
pathomorphological complete response (PMCR) the 
type of tumor was not defined. Tumor grades were well 
differentiated (G1) in 29 (13.4%) cases, moderately 
differentiated (G2) in 173 (79.7%) cases, and poorly 
differentiated (G3) in 15 (6.9%) cases. There were no 
nondifferentiated tumors.
In 15 (6%) patients no residual viable tumor cells 
(invasive or noninvasive) in resected specimens of the 
breast tumors and lymph nodes were found, that is why 
morphological and immunohistochemical analysis was 
not performed.
Lymph node metastases were revealed in 185 
(74.9%) patients, and none — in 55 (22.9%) patients.
There were 7 (2.8%) cases with total fibrosis and hya-
linosis in lymph nodes, assessed as absence of lymph 
node metastasis. There were 30 patients, with char-
acteristic for metastasis altered structure of lymphatic 
nodes, as detected by ultrasound examination. In these 
cases the metastasis in lymph nodes were not found by 
histological analysis as well. In 19 patients without lymph 
node metastasis in the preoperative period, lymph node 
metastases were found by histological study.
The number of lymph node metastases is a prognos-
tic criterion. In studied BC cases, metastasis in 1–3 lym-
phatic nodes were found in 78 (32.5%) cases, in 4–6 lym-
phatic nodes — in 69 (28.8%) cases, in 7–10 lymphatic 
nodes — in 38 (15.8%) cases. There were 24 (9.7%) 
patients with embolus in tumors vessels.
The number of lymphatic nodes with metastasis 
and embolus in tumor vessels characterize metastatic 
potential of the tumor. We have analyzed the relation 
between cases with different number of lymph node 
metastases and cases with embolus in tumor vessels, 
and have revealed that the patients negative by lymph 
node metastasis had no embolus in tumor vessels 
(Fig. 1). The number of lymph node metastases was 
positively associated with the presence of embolus in 
tumor vessels (p < 0.01).
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Fig. 1. Relation between embolus in tumors vessels and the 
number of lymph node metastases
Expression of ER/PR and Her-2/neu were analyzed 
by immunohistochemical method; in 15 cases with PMCR 
immunohistochemical analyzes was not available.
We have determined that 80 (34.5%) patients had 
basal BC subtype, 101 (43.5%) patients — luminal 
A subtype, 12 (5.2%) — luminal B subtype, and 39 
(16.8%) patients — Her-2/neu positive subtype.
There were only 5.2% patients with luminal B sub-
type of BC. The treatment and the course of the disease 
in these patients at higher degree depended on hyper-
expression of Her-2/neu, than on ER/PR expression. 
We combined luminal B and Her-2/neu subtypes: this 
combination looks feasible because both subtypes 
require similar chemotherapy with anthracyclines and 
targeted therapy with trastuzumab, and these patients 
belong to the group with high risk of disease relapse.
Efficacy of performed NACT was evaluated by 
patho morphological criteria and PMR grade. Rela-
tion between PMR and clinico-morphological and 
molecular prognostic factors was observed. The 
patients had different response rates after two identi-
cal NACT cycles: PMR grade 0–1 was registered in 
107 (43.3%) patients (Fig. 2, a), grade 2–3 — in 104 
(42.1%) cases (Fig. 2, b, c), grade 4–5 — in 36 (14.6%) 
patients (Fig. 2, d).
We have analyzed the factors affecting response 
rate and PMR grades. Relation between patients age 
and PMR grade are presented in Table1.
Table 1. The grade of pathological response in BC patients of different age
The PMR 30–39 years 40–49 years 50–59 years 60–70 yearsn % n % n % n %
0–1 9 40.9 30 53.6 44 41.9 24 37.5
2–3 5 22.7 16 28.5 50 47.6 33 51.6
4–5 8 36.4 10 17.9 11 10.5 7 10.9
All 22 100 56 100 105 100 64 100
Age less than 40 years was found to be a favorable 
predictor value for high grade PMR (p < 0.05). The 
morphological structure of tumor, its ER/PR status 
and proliferative activity depended on age of patients. 
In senior patients, there are well differentiated ER/PR 
positive tumors with low level of proliferative activity. 
The younger patients had poorly differentiated tumors 
with high level of proliferative activity, and often tumors 
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were ER/PR-negative or Her-2/neu positive [8, 12, 15]. 
So, the PMR grade seems not be depended from the 
age of patients from all age groups (χ2 = 5.84), and 
correlation between the age of patients and PMR grade 
was not found (rho = 0.02; p > 0.05).
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Fig. 2. BC tissue after NACT. a, PMR grade I; b, PMR grade II; c, 
PMR Grade III; d, PMR Grade IV; e, PMR Grade IV (hematoxiline-
eosin staining, 200X)
We have analyzed the correlation between tumor 
differentiation grade and PMR grade and determined 
that well differentited tumors (G1) had minimal response 
rate (0–1) in 96.6% (30 cases) of patients. Only in one 
G1 case, PMR grade 2 was found. There were no cases 
with PMCR in well differentiated tumors. In tumors with 
differentiation grade G2 we have found PMR grade 
0–1 in 44.5% (82 patients), grade 2–3 — in 53.8% 
(100 patients), grade 4–5 (PMCR) — in 1.7% (3 pa-
tients). In tumors with poor differentiation (G3), PMR 
grade 0–1 was detected in 18.7% (3 patients), grade 
2–3 — in 62.6% (10 patients), grade 4–5 — in 18.7% 
(3 patients). Relation between tumor differentiation 
grade and PMR grade is presented on Fig. 3. PMR grade 
is in opposite relation with tumor differentiation grade 
(χ2 = 31.33; р < 0.001). Well differentiated tumors had 
poor response rate in 96.6% cases, in 36.6% of them 
mucous cancer (7 cases) and papillary cancer (5 cases) 
were found, and these types of cancer belong to the 
types with favorable prognosis. There were no tumors 
with simultaneously both features: PMCR and high 
differentiation grade. So, we have demonstrated that 
there is a dependence between the tumor differentiation 
grade and PMR grade (p < 0.01), as well as significant 
correlation (rho = 0.38; p < 0.01).
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Fig. 3. Relation between PMR grade and tumor differentiation 
grade
The disease course is dependent on prognostic fac-
tors such as the number of lymph node metastases. We 
have analyzed the relation between tumor PMR grade 
and the number of lymph node metastases (Table 2).
Table 2. The relation between tumor PMR grade and the number of lymph 
node metastases
The number 
of lymph node 
metastases
PMR grade All cases0–І ІІ–ІІІ ІV–V
n % n % n % n %
0 26 47.3 26 47.3 3 5.4 55 100
1–3 33 42.3 36 46.2 9 11.5 78 100
4–6 30 43.5 27 39.1 12 17.4 69 100
7–10 18 47.4 15 39.5 5 13.1 38 100
It was found that PMR of grade 4–5 occur more 
often in the cases with lymph node metastases than 
in the cases without metastases in lymph nodes with 
(p < 0.05). There was no relation between the number 
of lymph node metastases, and there was relation be-
tween the PMR grade 4–5 and presence or absence 
of metastases in lymph nodes.
Embolus in tumor vessels were found in 24 (9.7%) 
of BC cases. We have analyzed a relation between 
PMR grade and the presence of embolus in tumor 
vessels. Embolus in tumor vessels were detected in 
7 (29.2%) patients with PMR of grade 0–1 (Fig. 4, a), 
2(8.3%) cases with PMR grade 2–3 (Fig. 4, b) and in 15 
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(62.5%) patients with PMR grade 4 (Fig. 4, c). The dif-
ference between the groups with PMR grade 0–1 and 
4–5 (29.9% vs. 62.5%, p < 0.001) and between the 
groups with PMR grade 2–3 and 4 (8.3% vs. 62.5%, 
p < 0.001) was statistically significant, as well as that 
between PMR grade 0–1 and 2–4 (29.9% vs. 8.3%) 
(Fig. 5). Embolus in tumor vessels were more common 
in PMR grade 4–5 cases than in PMR grade 0–1 and 
2–3 cases (p < 0.01). Groups of patients with the same 
PMR grade were different by such pattern as embolus 
in tumor vessels (χ2 = 17.8; р < 0.01).
The next step was to analyze the results of immu-
nohistochemical research, performed in 232 (96.0%) 
cases (in 15 (4.0%) from 247 cases there was PMCR, 
material not available). On the basis of immunohis-
tochemical research on ER/PR and Her-2/neu status, 
the BC tumors were classified on BC subtypes: basal 
subtype (80 (34.5%) cases), luminal A subtype (101 
(43.5%) cases), and Her-2/neu subtype (51 (22%) 
cases). We have analyzed the relation between the BC 
subtypes and PMR grade (Table 3).
a
b
c
Fig. 4. BC tissue after NACT, embolus in tumors vessels. a, PMR 
grade I; b, PMR grade II-III; c, PMR Grade IV (hematoxiline-eosin 
staining, 200X)
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Fig. 5. Relation between PMR grade and embolus in tumors 
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Table 3. Relation between BC subtypes and PMR grade
BC subtype
PMR grade All0–І ІІ–ІІІ ІV–V
n % n % n % n %
Basal 37 46.3 34 42.5 9 11.2 80 100
Luminal A 46 45.5 48 47.5 7 7.0 101 100
Her-2/neu+ 24 47.1 22 43.1 5 9.8 51 100
There were found no statistically significant dif-
ference and no correlation between PMR grade and 
subtype of BC (rho = 0.05; p > 0.05).
The 3-years death free survival (DFS) was in 66.8% 
(165 patients), the 3-years overall survival (OS) — 75.7% 
(187 patients). During 3-years after the treatment 60 
(24.3%) patients died. We defined that 3-years DFS of 
patients with PMR grade 0–1 was 66.3% (71 patients), 
with grade 2–3 — 77.9% (81 patients), and with grade 
4–5 — 36.1% (13 patients) (Fig. 6).
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Fig. 6. 3-years DFS of patients with different PMR grade
Analysis of survival curves by the method of Ka-
plan — Meier in groups of patients with different PMR 
grades after NACT (Fig. 6) has shown that survival 
was significantly higher in the group with PMR grade 
2–3, lower — in group with PMR grade 0–1, and the 
lo west — in patients with PMR grade 4–5 (χ2 = 25.5; 
p < 0.0001). It may be explained by the fact that BC tu-
mors with high mitotic activity and poor differentiation 
grade without expression of ER/PR are more sensitive 
to chemotherapy, but such patients have poor progno-
sis and more aggressive disease course [4, 5].
Then we have analyzed 3-years DFS in the groups 
of patients with identical BC subtypes dependent on 
PMR grade (Fig. 7). The rate of 3-years DFS of the 
patients with basal BC subtype with PMR grade 2–3 
(52.9%) was significantly higher than that of the pa-
tients with PMR grades 0–1 (28.6%) or 2–3 (22.6%) 
(p < 0.05). The curves of 3-years DFS of patients with 
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basal BC subtype and different PMR grades are shown 
on Fig. 8, a (χ2 = 15.176; р < 0.001). 
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a, basal subtype of BC; b, luminal A subtype of BC; c, Her-2/
neu subtype of BC
The highest 3-years DFS was revealed in the 
group with PMR grade. The curves of 3-years DFS of 
the patients with luminal A subtype of BC are shown 
on Fig. 8, b (χ2 = 14.9; р < 0.01). There was no sta-
tistically significant difference between the survival 
of patients with luminal A subtype with PMR grade 
0–1 and grade 2–3 (97.8% vs. 91.3%, p > 0.05). and 
the value of 3-years DFS of patients with PMR grade 
4–5 falls to 57.2% (p < 0.05). The curves of 3-years 
DFS of the patients with Her-2/neu subtypes are pre-
sented on Fig. 8, c (χ2 = 2.4; р > 0.05). So, we have 
demonstrated that 3-years DFS rates were dependent 
on PMR grade.
It was also determined an impact of PMR grade on 
the risk of disease relapse. The risk of disease relapse 
was found to depend on PMR grades: significantly de-
creased risk of relapse (HR = 0.71, 95% CI — 0.25–2.9, 
P = 0.0037) was determined in the cases of PMR grade 
2–3, while the highest risk of relapse (HR = –1.23, 
95% CI — 0.24–5.05, P = 0.0001) — in the patients 
with PMR grade 4-5, and no dependence between the 
parameters — in PMR grade 0–1 cases (HR = 0.22, 
95% CI; 0.08–0.38; P = 0.7).
The data of combined clinical, histological and 
immunohistochemical analysis have shown that PMR 
grades may serve as the criteria for individualization 
of adjuvant treatment of the patients with locally ad-
vanced BC.
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